Cosentyx V Stelara 52 week efficacy and safety study
#1
Results of a 52 week efficacy and safety study of Cosentyx v Stelara

Quote:
Background:
Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study.

Objective:
To compare the efficacy and safety of secukinumab vs ustekinumab over 52 weeks in CLARITY.

Methods:
Analysis of 52‐week data from CLARITY (NCT02826603), a phase 3b study in which patients were randomized to receive secukinumab 300 mg (n = 550) or ustekinumab 45/90 mg (n = 552) per label.

Results:
At week 52, secukinumab was superior to ustekinumab in the proportion of patients who achieved ≥90% improvement in Psoriasis Area and Severity Index (73.2% vs 59.8%; odds ratio [OR], 1.84 [95% CI, 1.41‐2.41]; P < .0001), Investigator’s Global Assessment modified 2011 responses of clear (0) or almost clear (1) skin (76.0% vs 60.2%; OR, 2.12 [95% CI, 1.61‐2.79]; P < .0001), and Dermatology Life Quality Index response of no effect (0/1) (69.9% vs 61.2%; P = .0028). Proportions of patients with any adverse events were comparable between treatment arms.

Conclusions:
This second head‐to‐head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials.

Source: onlinelibrary.wiley.com

*Early view funding unknown

[post=44218]

[post=168]
Reply
#2
The star of Cosentyx keeps on rising. Smile

But ... I still cannot read the statistics that are contained in the research... very annoying.

So... I bought a book of a well known Dutch teacher, who was formerly knows as one of the math girls. She, Ionica, is a professor in mathematics now and knows everything about statistics. So I am reading that first and now are beginning to realise that numbers in statistics are very difficult to interpret. It contains rules that are not obvious.
I may (not will) give an example later on. It is a very readable book, but that is because it is in Dutch. Rolleyes

I also found an old and very large book called “Statistics” by Shaum. It is an ugly purple softcover book, but... it looks very professional. Now finding the time to study it. Whistle
Reply
#3
You have more patience than me Caroline Statistics is a difficult subject Clap
Reply


Possibly Related Threads…
Thread Author Replies Views Last Post
  Cosentyx and low-density lipoprotein cholesterol Fred 0 529 Mon-12-10-2026, 11:43 AM
Last Post: Fred
  Bimzelx efficacy and safety in Chinese patients Fred 0 1,438 Mon-25-05-2026, 12:43 PM
Last Post: Fred
  Efficacy and safety of Imsidolimab for pustular psoriasis Fred 0 1,248 Wed-29-04-2026, 14:58 PM
Last Post: Fred
  Kyntheum / Siliq and palmoplantar psoriasis study Fred 0 1,261 Sun-26-04-2026, 13:14 PM
Last Post: Fred
  Biologic efficacy in patients with psoriasis (study) Fred 0 1,204 Sat-18-04-2026, 11:42 AM
Last Post: Fred



Users browsing this thread: 1 Guest(s)